ESGO 2021 | KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer

Nicoletta Colombo, MD, PhD, European Institute of Oncology, Milan, Italy & University of Milan-Bicocca, Milan, Italy, presents an update from KEYNOTE-826 (NCT03635567), a double-blind Phase III trial evaluating pembrolizumab versus placebo in patients with persistent, recurrent, or metastatic cervical cancer. As recently published, pembrolizumab in this patient population resulted in a significantly longer progression-free and overall survival. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.